Moreover, checkpoint inhibitors likely benefit a broader range of patients across trials, such as pembrolizumab and nivolumab representing key checkpoint inhibitor immunotherapies used today, but their success remains conditional on tumor type together with PD-L1 expression and other pertinent biomarkers [18,29]. This evidence concerns the gene CD274 and neoplasm.